

## Special Issue

# Advances in the Management of Oligometastatic Disease in Non-colorectal Non-neuroendocrine Tumors

### Message from the Guest Editor

Most metastatic solid tumors present with multiple and multiorgan spread and are associated with high mortality rates. The oligometastatic disease concept was first described in 1995 by Hellman and Weichselbaum. It is defined as low volume metastatic disease with a limited number and size of metastatic lesions. Surgery has become a potential curative treatment for patients with **colorectal** and neuroendocrine **liver metastases**. Therefore, it has entered clinical practice and is now the standard treatment. By contrast, surgical treatment for non-colorectal, non-neuroendocrine oligometastatic disease has always been considered marginal and remains poorly investigated. Nevertheless, surgery has been suggested as an available form of treatment in a subset of patients, supported by recent evidence from various high-volume centers. In oligometastatic disease management, surgery with radical intent should be investigated more to highlight its role in terms of overall survival, relapse of cancer, and quality of life.

### Guest Editor

Dr. Stefania Brozzetti

Department of Surgery "Pietro Valdoni", Policlinico Umberto I,  
University of Rome La Sapienza, Roma, Italy

### Deadline for manuscript submissions

closed (31 December 2023)



## Cancers

an Open Access Journal  
by MDPI

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/126690](https://mdpi.com/si/126690)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)